May 17, 2020

Porn fuels increasing demand for 'designer vaginas'

designer vagina
Cosmetic surgery
procedure
increasing dem
Admin
2 min
More women are seeking a designer vagina
As part of Healthcare Global's 2011 review, we've revisited this story which originally made the headlines in August... The number of women see...

As part of Healthcare Global's 2011 review, we've revisited this story which originally made the headlines in August...

The number of women seeking genital cosmetic surgery in the quest for a ‘designer vagina’ has risen dramatically in the last decade.

In the UK alone, the number of women seeking the procedure on the NHS has increased by five times and it is believed thousands more could have had the operation privately.

Researchers found the average age of designer vagina hunters is 23, but most women only want to undergo cosmetic surgery for aesthetic reasons.

They have linked the interest in genital surgery to pornography and an increasing pressure for women to look perfect.

In a study of 33 women having vaginal surgery, 60 percent wanted to make their labia smaller to improve its appearance, despite the researchers saying they were normal in size.

Only three of the women were recommended for the procedure to address a significant asymmetry.

One of the researchers, Sarah Creighton from the UCL Elizabeth Garrett Anderson Institute of Women's Health, said: “It is surprising that all of the study participants had normal sized labia minora and despite this nearly half were still keen to pursue surgery as an option.  

“A particular concern is the age of some of the referred patients, one as young as 11 years old.

She added: “Development of the external genitalia continues throughout adolescence and in particular the labia minora may develop asymmetrically initially and become more symmetrical in time."

Meanwhile, experts are warning doctors need to be issued with clear guidelines on when patients should be referred to hospitals for such surgery.

The results of the research have been published in BJOG: An International Journal of Obstetrics and Gynaecology and the Deputy Editor-in-Chief, Pierre Martin-Hirsch said: “Many women who are worried may have normal sized labia minora. Clear guidance is needed for clinicians on how best to care for women seeking surgery.”

Our magazine is now available on the iPad. Click here to download it.

Share article

Jun 16, 2021

NHS opens 8 clinical trial sites to assess cancer treatment

NHS
Cancer
immunotherapy
MachineLearning
2 min
NHS and OncoHost to launch clinical trials analysing cancer patients response to immunotherapy

The UK's National Health Service (NHS) is opening eight clinical trial sites to assess patients' responses to personalised cancer therapy. 

The trials will analyse how patients diagnosed with advanced melanoma or non-small cell lung cancer respond to immunotherapy, to help predict their response to treatment.  They will be hosted at Gloucestershire Hospitals NHS Foundation Trust facilities. 

Immunotherapy helps the body's own immune system fight cancer, but while it has achieved good results for some cancer patients, it is not successful for everyone. Finding ways to predict which people will respond to the treatment is a major area of research.

OncoHost, an oncology startup,  will provide advanced machine learning technology to develop personalised strategies aiming to improve the success rate of the cancer therapy. The trials will contribute to OncoHost’s ongoing PROPHETIC study, which uses the company’s host response profiling platform, PROphet®

“Immunotherapy has achieved excellent results in certain situations for several cancers, allowing patients to achieve longer control of their cancer with maintained quality of life and longer survival,” said Dr David Farrugia, Consultant Medical Oncologist at NHS, and chief investigator of all eight NHS clinical trial sites.

“However, success with immunotherapy is not guaranteed in every patient, so this PROPHETIC study is seeking to identify changes in proteins circulating in the blood which may help doctors to choose the best treatment for each patient." 

"I am excited that Gloucestershire Oncology Centre and its research department have this opportunity to contribute to this growing field of research and I am determined that our centre will make a leading national contribution in patient recruitment.”

Previous studies in the US and Israel have shown that PROphet® has high accuracy in predicting how patients with cancer will respond to various therapies.

Share article